The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LIGAND: A versatile computerized approach for characterization of ligand-binding systems
Munson, P. J., & Rodbard, D. (1980) · Analytical Biochemistry · doi:10.1016/0003-2697(80)90515-1 · Cited by 8,429
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Sokoloff, P., Giros, B., Martres, M.-P., Bouthenet, M.-L., & Schwartz, J.-C. (1990) · Nature · doi:10.1038/347146a0 · Cited by 2,609
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Van Tol, H. H. M., Bunzow, J. R., Guan, H.-C., Sunahara, R. K., Seeman, P., Niznik, H. B., & Civelli, O. (1991) · Nature · doi:10.1038/350610a0 · Cited by 2,014
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Farde, L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820070032005 · Cited by 1,419
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Self-citationKapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
The Effects of Clozapine, Risperidone, and Olanzapine on Cognitive Function in Schizophrenia
Meltzer, H. Y., & McGurk, S. R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033376 · Cited by 1,020
Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801
Self-citationSerotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Self-citationDo Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence
Arnt, J. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00112-7 · Cited by 715
Agonist-receptor efficacy II: agonist trafficking of receptor signals
Kenakin, T. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)89032-x · Cited by 657
Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624
Monsma, F. J., Shen, Y., Ward, R. P., Hamblin, M. W., & Sibley, D. R. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13616-x · Cited by 597
Self-citationChoudhary, M. S., Craigo, S., Sibley, D. R., Roth, B. L., Monsma, F. J., Shen, Y., Uluer, A., & Meltzer, H. Y. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/74zp-ze10 · Cited by 592
Self-citationPotkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G., & Marder, S. R. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.681 · Cited by 591
Novel antipsychotics: comparison of weight gain liabilities.
Wirshing, D. A., Wirshing, W. C., Kysar, L., Berisford, M. A., Goldstein, D., Pashdag, J., Mintz, J., & Marder, S. R. (1999) · PubMed · Cited by 523
The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor
Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., & Altar, C. A. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01532-7 · Cited by 512
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
Shen, Y., Monsma, F. J., Metcalf, M. A., Jose, P. A., Hamblin, M. W., & Sibley, D. R. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46830-x · Cited by 507
Self-citationKeck, P. E., Marcus, R., Tourkodimitris, S., Ali, M., Liebeskind, A., Saha, A., Ingenito, G., & Aripiprazole Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1651 · Cited by 501
Marder, S. R., McQuade, R. D., Stock, E., Kaplita, S., Marcus, R., Safferman, A. Z., Saha, A., Ali, M., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467
Possible Role of Valvular Serotonin 5-HT2B Receptors in the Cardiopathy Associated with Fenfluramine
Fitzgerald, L. W., Burn, T. C., Brown, B. S., Patterson, J. P., Corjay, M. H., Valentine, P. A., Sun, J.-H., Link, J. R., Abbaszade, I., Hollis, J. M., et al. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26444-0 · Cited by 440
Lawler, C. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00099-2 · Cited by 408
Novel Antipsychotics: Comparison of Weight Gain Liabilities
Wirshing, D. A., Wirshing, W. C., Kysar, L., Berisford, M. A., Goldstein, D., Pashdag, J., Mintz, J., & Marder, S. R. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0602 · Cited by 393
Schoemaker, H., Claustre, Y., Fage, D., Rouquier, L., Chergui, K., Curet, O., Oblin, A., Gonon, F., Carter, C., Benavides, J., et al. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36395-5 · Cited by 371
Dopamine Partial Agonists: A New Class of Antipsychotic
Lieberman, J. A. (2004) · CNS Drugs · doi:10.2165/00023210-200418040-00005 · Cited by 340
Martı́n-Ruiz, R., Puig, M. V., Celada, P., Shapiro, D. A., Roth, B. L., Mengod, G., & Artigas, F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09856.2001 · Cited by 339
Self-citation5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential
Martin, J. R., Bös, M., Jenck, F., Moreau, J.-L., Mutel, V., Sleight, A. J., Wichmann, J., Andrews, J. S., Berendsen, H. H. G., Broekkamp, C. L. E., et al. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37669-4 · Cited by 334
Environmental-Dependent Acceleration of a Developmental Switch: The Floral Transition
Simpson, G. G., & Dean, C. (2000) · Science's STKE · doi:10.1126/stke.2000.18.pe1 · Cited by 318
Yokoi, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00304-4 · Cited by 313
Pigott, T. A., Carson, W. H., Saha, A. R., Torbeyns, A. F., Stock, E. G., Ingenito, G. G., & Aripiprazole Study Group (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0910 · Cited by 309
Kasper, S., Lerman, M. N., McQuade, R. D., Saha, A., Carson, W. H., Ali, M., Archibald, D., Ingenito, G., Marcus, R., & Pigott, T. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003651 · Cited by 309
Receptor pharmacology of neuroleptics: relation to clinical effects.
Richelson, E. (1999) · PubMed · Cited by 306
Reduced satiating effect of d -fenfluramine in serotonin 5-HT 2C receptor mutant mice
Vickers, S. P., Clifton, P. G., Dourish, C. T., & Tecott, L. H. (1999) · Psychopharmacology · doi:10.1007/s002130050952 · Cited by 291
Kikuchi, T., Tottori, K., Uwahodo, Y., Hirose, T., Miwa, T., Oshiro, Y., & Morita, S. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10600-9 · Cited by 276
Efficacy at g-protein-coupled receptors
Kenakin, T. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd722 · Cited by 263
Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study
on behalf of the Aripiprazole Study Group, Casey, D. E., Carson, W. H., Saha, A. R., Liebeskind, A., Ali, M. W., Jody, D., & Ingenito, G. G. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1344-3 · Cited by 250
BindingDB (2011) · PubMed · doi:10.7270/q2154fjq · Cited by 224
Multiple Serotonin Receptors: Clinical and Experimental Aspects
Roth, B. (1994) · Annals of Clinical Psychiatry · doi:10.3109/10401239409148985 · Cited by 213
Self-citationAn economic evaluation of schizophrenia-1991
Wyatt, R. J., Henter, I., Leary, M. C., & Taylor, E. (1995) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00789054 · Cited by 200
Mechanism of New Antipsychotic Medications: Occupancy Is Not Just Antagonism
Gründer, G., Carlsson, A., & Wong, D. F. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.10.974 · Cited by 199
Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors.
Roth, B. L., Ciaranello, R. D., & Meltzer, H. Y. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11452-3 · Cited by 197
Self-citationAtypical antipsychotic agents: A critical review
Worrel, J. A., Marken, P. A., Beckman, S. E., & Ruehter, V. L. (2000) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/57.3.238 · Cited by 194
Neve, K. A., Cox, B. A., Henningsen, R. A., Spanoyannis, A., & Neve, R. L. (1991) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11081-x · Cited by 189
Mallikaarjun, S., Salazar, D. E., & Bramer, S. L. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003261901 · Cited by 178
Bhatnagar, A., Willins, D. L., Gray, J. A., Woods, J., Benovic, J. L., & Roth, B. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006968200 · Cited by 163
Self-citationStahl, S. M. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0102 · Cited by 153
Partial dopamine agonists in the treatment of psychosis
Tamminga, C. A. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200033 · Cited by 150
Rauser, L., Savage, J. E., Meltzer, H. Y., & Roth, B. L. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29304-6 · Cited by 144
Self-citationRoth, B. L., Tandra, S., Burgess, L. H., Sibley, D. R., & Meltzer, H. Y. (1995) · Psychopharmacology · doi:10.1007/bf02311185 · Cited by 143
Self-citationOshiro, Y., Sato, S., Kurahashi, N., Tanaka, T., Kikuchi, T., Tottori, K., Uwahodo, Y., & Nishi, T. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm940608g · Cited by 143
Psychotropic drugs and the ECG: focus on the QTc interval
Goodnick, P. J., Parra, F., & Jerry, J. M. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.5.479 · Cited by 139
Stahl, S. M. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1201 · Cited by 135
Aripiprazole: profile on efficacy and safety
Goodnick, P. J., & Jerry, J. M. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.12.1773 · Cited by 130
Antipsychotics: impact on prolactin levels
Goodnick, P. J., Santana, O., & Rodriguez, L. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.10.1381 · Cited by 124
Mottola, D. M., Kilts, J. D., Lewis, M. M., Connery, H. S., Walker, Q. D., Jones, S. R., Booth, R. G., Hyslop, D. K., Piercey, M., Wightman, R. M., et al. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1166 · Cited by 123
Self-citationIn vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function
Jordan, S., Koprivica, V., Dunn, R. W., Tottori, K., Kikuchi, T., & Altar, C. A. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.10.025 · Cited by 117
Partial Dopamine Agonists and Dopaminergic Stabilizers, in the Treatment of Psychosis
Tamminga, C. A., & Carlsson, A. (2002) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007024606195 · Cited by 113
Shapiro, D. A., Kristiansen, K., Kroeze, W. K., & Roth, B. L. (2000) · Molecular Pharmacology · doi:10.1124/mol.58.5.877 · Cited by 111
Self-citationInoue, A., Miki, S., Seto, M., Kikuchi, T., Morita, S., Ueda, H., Misu, Y., & Nakata, Y. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00920-x · Cited by 105
Gray, J. A., Sheffler, D. J., Bhatnagar, A., Woods, J. A., Hufeisen, S. J., Benovic, J., & Roth, B. L. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.5.1020 · Cited by 100
Self-citationLong-Term Olanzapine Therapy in the Treatment of Bipolar I Disorder
Sanger, T. M., Grundy, S. L., Gibson, P. J., Namjoshi, M. A., Greaney, M. G., & Tohen, M. F. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0410 · Cited by 99
α2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs
Kalkman, H. O., & Loetscher, E. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01308-6 · Cited by 96
Regulation of dopamine D2 receptors by sodium and pH.
Neve, K. A. (1991) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)11023-7 · Cited by 94
Semba, J., Watanabe, A., Kito, S., & Toru, M. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00059-f · Cited by 93
Muscarinic m4 receptor activation by some atypical antipsychotic drugs
Zeng, X. P., Le, F., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00956-9 · Cited by 93
N1-(Benzenesulfonyl)tryptamines as novel 5-HT6 antagonists
Tsai, Y., Dukat, M., Slassi, A., MacLean, N., Demchyshyn, L. L., Savage, J. E., Roth, B. L., Hufesein, S., Lee, M., & Glennon, R. A. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00453-4 · Cited by 93
Self-citationInoue, T., Domae, M., Yamada, K., & Furukawa, T. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12799-7 · Cited by 92
Zhang, L. J., Lachowicz, J. E., & Sibley, D. R. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10202-2 · Cited by 89
Self-citationARIPIPRAZOLE: A REVIEW OF ITS PHARMACOLOGY AND CLINICAL USE
Taylor, D. M. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb11397.x · Cited by 88
Stanton, T., Watson, C. B., Cusack, B. M., & Richelson, E. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90211-e · Cited by 84
Kilts, J. D., Connery, H. S., Arrington, E. G., Lewis, M. M., Lawler, C. P., Oxford, G. S., O’Malley, K. L., Todd, R. D., Blake, B. L., Nichols, D. E., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.1179 · Cited by 83
Self-citationAtypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’?
Roth, B. L., Sheffler, D. J., & Potkin, S. G. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00021-5 · Cited by 80
Self-citationModeling and Mutational Analysis of a Putative Sodium-Binding Pocket on the Dopamine D2 Receptor
Neve, K. A., Cumbay, M. G., Thompson, K. R., Yang, R., Buck, D. C., Watts, V. J., DuRand, C. J., & Teeter, M. M. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.2.373 · Cited by 79
Egan, C. T., Grinde, E., DuPre, A., Roth, B. L., Hake, M., Teitler, M., & Herrick‐Davis, K. (2000) · Synapse · Cited by 78
Self-citationAripiprazole: A New Atypical Antipsychotic Drug
Bowles, T. M., & Levin, G. M. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c297 · Cited by 74
Aihara, K., Shimada, J., Miwa, T., Tottori, K., Burris, K. D., Yocca, F. D., Horie, M., & Kikuchi, T. (2004) · Brain Research · doi:10.1016/j.brainres.2003.09.082 · Cited by 63
Aripiprazole-Induced Improvement in Tardive Dyskinesia
Duggal, H. S. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304801116 · Cited by 60
Sugiyama, A., Satoh, Y., & Hashimoto, K. (2001) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2001.9168 · Cited by 55
Aripiprazole, a Novel Atypical Antipsychotic Drug
Argo, T. R., Carnahan, R. M., & Perry, P. J. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.2.212.33145 · Cited by 52
Binding of Typical and Atypical Antipsychotic Drugs to Multiple Neurotransmitter Receptors
Roth, B. L., Meltzer, H. Y., & Khan, N. A. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60793-0 · Cited by 46
Self-citationNakai, S., Hirose, T., Uwahodo, Y., Imaoka, T., Okazaki, H., Miwa, T., Nakai, M., Yamada, S., Dunn, B., Burris, K. D., et al. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01857-0 · Cited by 43
Keltner, N. L., & Johnson, V. (2002) · Perspectives In Psychiatric Care · doi:10.1111/j.1744-6163.2002.tb01566.x · Cited by 43
Paradoxical regulation of dopamine receptors in transfected 293 cells.
Filtz, T. M., Artymyshyn, R. P., Guan, W., & Molinoff, P. B. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13181-7 · Cited by 40
Worsened Agitation With Aripiprazole: Adverse Effect of Dopamine Partial Agonism?
DeQuardo, J. R. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0122b · Cited by 38
Psychopharmacology: Atypical Antipsychotic Dosing: The Effect of Co-medication With Anticonvulsants
de León, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.2.125 · Cited by 37
Aripiprazole and Parkinson’s Disease Psychosis
Schönfeldt‐Lecuona, C., & Connemann, B. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.2.373-a · Cited by 36
Does olanzapine have antidepressant properties? A retrospective preliminary study
Ghaemi, S. N., Cherry, E. L., Katzow, J. J., & Goodwin, F. K. (2000) · Bipolar Disorders · doi:10.1034/j.1399-5618.2000.020307.x · Cited by 35
Aripiprazole: A novel antipsychotic with dopamine stabilizing properties.
Rivas-Vazquez, R. A. (2003) · Professional Psychology Research and Practice · doi:10.1037/0735-7028.34.1.108 · Cited by 35
ARIPIPRAZOLE AND EXTRAPYRAMIDAL SYMPTOMS
Lindsey, R. L., Kaplan, D., Koliatsos, V. E., Walters, J. K., & Sandson, N. B. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000095540.18151.b0 · Cited by 31
Green, B. (2004) · Current Medical Research and Opinion · doi:10.1185/030079903125002919 · Cited by 29
Roth, B. L., Willins, D. L., Kristiansen, K., & Kroeze, W. K. (1999) · The Neuroscientist · doi:10.1177/107385849900500414 · Cited by 28
Self-citationSafety and tolerability of aripiprazole at doses higher than 30 mg
Auby, P., Saha, A. R., Ali, M., Ingenito, G. G., Wilber, R. B., & Bramer, S. L. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)80406-0 · Cited by 28
Evidence-based pharmacotherapy of schizophrenia
Emsley, R. A., & Oosthuizen, P. P. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004171 · Cited by 27
Marona‐Lewicka, D., & Nichols, D. E. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1677-6 · Cited by 27
Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo
Carson, W. H., Kane, J. M., Ali, M. W., Dunbar, G. C., & Ingenito, G. G. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80358-2 · Cited by 25
Treatment for mood and anxiety disorders: Quetiapine and aripiprazole
Sajatovic, M. (2003) · Current Psychiatry Reports · doi:10.1007/s11920-003-0062-9 · Cited by 23
P.2.127 Aripiprazole in pediatric-conduct disorder: A pilot study
Findling, R. L., Blumer, J. L., Kauffman, R., Batterson, J. R., Gilbert, D. L., Bramer, S. L., & Marcus, R. N. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92080-3 · Cited by 22
New Developments in the pharmacotherapy of schizophrenia
Fleischhacker, W. W. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6020-6_7 · Cited by 20
Similarities and differences among antipsychotics.
Tamminga, C. A. (2003) · PubMed · Cited by 17
Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder
Potkin, S. G., Kujawa, M. J., Carson, W. H., Saha, A. R., Ali, M. D. A., & Ingenito, G. G. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)80511-x · Cited by 15
P.2.121 Aripiprazole vs. haloperidol for maintained treatment effect in acute mania
Bourin, M., Auby, P., Swanik, S., Marcus, R. N., McQuade, R. D., Iwamoto, T., & Sanchez, R. (2003) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(03)92074-8 · Cited by 14
Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia
Carson, W., McQuade, R. D., Saha, A. R., Torbeyns, A. F., & Stock, E. G. (2002) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(02)80404-7 · Cited by 12
Meta-analysis of the efficacy of aripiprazole in schizophrenia
Carson, W. H., Saha, A. R., Stringfellow, J., Archibald, D., Marcus, R. N., Kujawa, M. J., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)80439-5 · Cited by 3
Cited by
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Self-citationFunctional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,116
Self-citationMiyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308947200 · Cited by 913
Self-citation
Metadata
- Authors
- Shapiro, D. A., Renock, S., Arrington, E., Chiodo, L. A., Liu, L.-X., Sibley, D. R., Roth, B. L., & Mailman, R.
- Venue
- Neuropsychopharmacology
- Published
- 2003-03-27
- Volume
- 28
- Issue
- 8
- Pages
- 1400-1411
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2070357412
- Cited by
- 968
- References
- 110
- FWCI
- 20.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.